Neurocrine Biosciences, Inc.
NBIX
$128.91
$0.680.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 687.50M | 572.60M | 627.70M | 622.10M | 590.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 687.50M | 572.60M | 627.70M | 622.10M | 590.20M |
| Cost of Revenue | 255.60M | 272.40M | 194.90M | 203.00M | 200.30M |
| Gross Profit | 431.90M | 300.20M | 432.80M | 419.10M | 389.90M |
| SG&A Expenses | 286.30M | 276.50M | 301.80M | 234.30M | 242.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 541.90M | 548.90M | 496.70M | 437.30M | 442.30M |
| Operating Income | 145.60M | 23.70M | 131.00M | 184.80M | 147.90M |
| Income Before Tax | 159.50M | 14.70M | 162.60M | 190.30M | 98.60M |
| Income Tax Expenses | 52.00M | 6.80M | 59.50M | 60.50M | 33.60M |
| Earnings from Continuing Operations | 107.50M | 7.90M | 103.10M | 129.80M | 65.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.50M | 7.90M | 103.10M | 129.80M | 65.00M |
| EBIT | 145.60M | 23.70M | 131.00M | 184.80M | 147.90M |
| EBITDA | 152.90M | 31.30M | 138.10M | 191.30M | 155.20M |
| EPS Basic | 1.09 | 0.08 | 1.03 | 1.28 | 0.64 |
| Normalized Basic EPS | 1.05 | 0.28 | 0.96 | 1.29 | 1.06 |
| EPS Diluted | 1.06 | 0.08 | 1.00 | 1.24 | 0.63 |
| Normalized Diluted EPS | 1.03 | 0.28 | 0.93 | 1.25 | 1.03 |
| Average Basic Shares Outstanding | 99.00M | 99.70M | 100.00M | 101.10M | 100.80M |
| Average Diluted Shares Outstanding | 101.00M | 102.50M | 102.90M | 104.30M | 103.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |